ExpreS2ion Biotech
ExpreS2ion hosts informative webinar on 2024 Rights Issue and Highlights Key Updates on HER2+ Breast Cancer Vaccine
Background and rationale for the 2024 rights issue
During the webinar, CEO Bent Frandsen elaborated on the strategic importance of the rights issue. He emphasized that the additional capital will bolster the Company's ongoing efforts in advancing its pipeline of innovative therapeutics and vaccines. In particular, this capital injection is critical for initiating the phase I clinical trial of ES2B-C001, the Company’s groundbreaking therapeutic HER2+ breast cancer vaccine.
CEO Bent Frandsen’s presentations with emphasis on ES2B-C001:
- H.C. Andersen Capital Life Science Seminar on 4 June 2024, Watch the presentation.
- BioStock Global Forum on 30 May 2024, Watch the presentation.
Additional resources
For comprehensive information about the 2024 Rights Issue, including the full prospectus and a step-by-step subscription guide, visit the ExpreS2ion investor relations site, under IPO and Rights Issues. Presentation recordings providing further insights into the development and potential of the ES2B-C001 vaccine are also available on the investor relations website, under Presentations.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.
| Datum | 2024-06-18, kl 13:00 |
| Källa | Cision |
Kom igång med ditt sparande på bara några minuter! Hos Avanza handlar du aktier från 0 kr på Stockholmsbörsen och får tillbaka alla fondavgifter (ja, alla!) upp till 50 000 kr i samlat sparande. Kanske är det därför Avanza har Sveriges nöjdaste sparare 15 år i rad.